. 2022 Jun 9;9:905085. doi: 10.3389/fmed.2022.905085

TABLE 4.

Weighted odds ratios (95% confidence intervals) for insulin resistance (HOMA-IR) of participants across quartiles of serum uric acid (Men = 2,498, women = 2,650).

	Case/Participants	Crude^a	Model 1^a	Model 2^a
Men^†
Q1	635/2,498	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
Q2	685/2,498	1.6 (1.1–2.3) ^*	1.6 (1.1–2.3) ^*	1.2 (0.7–1.9)
Q3	567/2,498	3.2 (2.2–4.8) ^**	3.2 (2.1–4.8) ^**	1.9 (1.1–3.4) ^*
Q4	611/2,498	4.6 (3.3–6.6) ^**	4.8 (3.4–6.7) ^**	1.9 (1.1–3.1) ^*
Women^†
Q1	663/2,650	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
Q2	694/2,650	1.7 (1.2–2.5) ^**	1.9 (1.3–2.7) ^**	1.3 (0.7–2.5)
Q3	648/2,650	2.3 (1.4–3.6) ^**	2.5 (1.5–3.9) ^**	1.3 (0.6–2.5)
Q4	645/2,650	5.9 (3.8–9.1) ^**	6.6 (4.2–10.4) ^**	2.2 (1.2–4.3) ^*

^aCalculated using binary logistic regression.

^†Men: Q1 (uric acid ≤ 309.30 μmol/L), Q2 (309.30 < uric acid ≤ 356.90 μmol/L), Q3 (356.90 < uric acid ≤ 404.50 μmol/L), and Q4 (uric acid > 404.50 μmol/L). Women: Q1 (uric acid ≤ 232.00 μmol/L), Q2 (232.00 < uric acid ≤ 273.60 μmol/L), Q3 (273.60 < uric acid ≤ 321.20 μmol/L), and Q4 (uric acid > 321.20 μmol/L).

Model 1 adjusted for race.

Model 2 adjusted for race, body mass index, waist circumference, drinking status, education level, hypertension, serum triglyceride, total cholesterol, and urate-lowering therapy.

*P < 0.05.

**P < 0.01.